Cancer Immunotherapy Market & Clinical Pipeline Insight

Description: With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments.

There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body's immune system in order to target the cancer.

The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system.

There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.

Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.

- Cancer Immunotherapy Market & Clinical Pipeline Insight - Report Highlights:
  - Cancer Immunotherapy Market Overview
  - Cancer Immunotherapy Market Dynamics
  - Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
  - Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
  - Cancer Vaccine Clinical Pipeline by Phase & Country
  - Oncolytic Viruses Clinical Pipeline by Phase & Country
  - Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
  - Cancer Cell Therapy Clinical Trial Insight by Phase & Country
  - Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

Contents:

1. Introduction to Cancer Immunotherapy
2. Mechanism of Cancer Immunotherapy
   2.1 Genetic engineering
   2.2 Hybridoma Technology
   2.3 Humanization of Monoclonal Antibodies
   2.4 Overcoming the HAMA Response via Modern Technology
3. Types of Cancer Immunotherapy
   3.1 Monoclonal Antibodies
3.2 Checkpoint Inhibitors
3.3 Vaccination
3.4 Non Specific Immunotherapies

4. Why Need for Cancer Immunotherapy

5. Global Cancer Immunotherapy Market Overview

6. Cancer Immunotherapy Market Dynamics
   6.1 Favorable Market Drivers
   6.2 Key issues to be Discussed
   6.3 Future of Cancer Immunotherapy

7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
   7.1 Clinical Pipeline Overview
   7.2 Clinical Pipeline Insight: Research till Registration
   7.3 Marketed Cancer Monoclonal Antibodies

8. Cancer Vaccine Clinical Pipeline by Phase & Country
   8.1 Clinical Pipeline Overview
   8.2 Clinical Pipeline Insight: Research till Registration
   8.3 Marketed Cancer Vaccines

9. Oncolytic Viruses Clinical Pipeline by Phase & Country
   9.1 Clinical Pipeline Overview
   9.2 Clinical Pipeline Insight: Research till Registration

10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
   10.1 Clinical Pipeline Overview
   10.2 Clinical Pipeline Insight: Research till Preregistration
   10.3 Marketed Cancer Cytokines Therapy

11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country
   11.1 Clinical Pipeline Overview
   11.2 Clinical Pipeline Insight: Research till Preregistration
   11.3 Marketed Cancer Cell Therapy

12. Competitive Landscape: Business Overview & Product Pipeline
   12.1 Advaxis
   12.2 Celldex Therapeutics
   12.3 Dendreon Corporation
   12.4 Galena Biopharma
   12.5 ImmunoCellular Therapeutics
   12.6 ImmunoGen
   12.7 Inovio Pharmaceuticals
   12.8 Merck
   12.9 NeoStem Oncology
   12.10 NewLink Genetics
   12.11 Northwest Biotherapeutics
   12.12 Novartis
   12.13 Peregrine Pharmaceuticals
   12.14 Roche
   12.15 Seattle Genetics

List Of Figures:

Figure 1-1: Introduction to Cancer Therapies
Figure 1-2: Key Events in the History of Cancer Immunotherapy
Figure 2-1: Mechanism of Cancer Immunotherapy
Figure 3-1: Type of Cancer Immunotherapy
Figure 5-1: Cancer Immunotherapy Market Category
Figure 5-2: Cancer Immunotherapy Market US$ Billion, 2014-2020
Figure 5-3: Cancer Immunotherapy Market by Region %, 2014 & 2020
Figure 5-4: Regulatory Milestones for Cancer Immunotherapy

Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase %, 2014
Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase Number, 2014

Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase %, 2014
Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase Number, 2014

Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase %, 2014
Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase Number, 2014

Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase %, 2014
Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase Number, 2014

Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase %, 2014
Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase Number, 2014

Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: Celldex Therapeutics Clinical Pipeline
Figure 12-3: Galena Biopharma Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: ImmunoGen Clinical Pipeline
Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 12-10: Seattle Genetics Clinical Pipeline

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2890713/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

**Product Name:** Cancer Immunotherapy Market & Clinical Pipeline Insight
**Web Address:** http://www.researchandmarkets.com/reports/2890713/
**Office Code:** SCD2ST8Y

**Product Formats**
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Description</th>
<th>Price Until 10th Jul 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy:</td>
<td></td>
<td></td>
<td>USD 3780 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 4200</td>
<td><strong>Until 10th Jul 2016</strong></td>
</tr>
<tr>
<td>CD-ROM:</td>
<td></td>
<td></td>
<td>USD 3240 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 3600</td>
<td><strong>Until 10th Jul 2016</strong></td>
</tr>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td></td>
<td>USD 2700</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 3000</td>
<td><strong>Until 10th Jul 2016</strong></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td></td>
<td>USD 5400</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 6000</td>
<td><strong>Until 10th Jul 2016</strong></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

---

**Contact Information**
Please enter all the information below in **BLOCK CAPITALS**

**Title:**

- [ ] Mr
- [ ] Mrs
- [ ] Dr
- [ ] Miss
- [ ] Ms
- [ ] Prof

**First Name:** __________________________
**Last Name:** __________________________

**Email Address:** *

**Job Title:** __________________________

**Organisation:** _________________________

**Address:** ____________________________

**City:** _______________________________

**Postal / Zip Code:** ____________________

**Country:** ____________________________

**Phone Number:** ________________________
Title:  
Fax Number:  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World